Sanofi joins the al­pha-synu­cle­in band­wag­on, hand­ing Ko­re­an biotech $75M for pre­clin­i­cal bis­pe­cif­ic

Al­pha-synu­cle­in is gain­ing clout in the grow­ing ef­fort to crush Parkin­son’s dis­ease at its roots.

Sanofi be­came the lat­est to join the gang late Tues­day, turn­ing to Ko­rea’s ABL Bio to li­cense a pre­clin­i­cal bis­pe­cif­ic an­ti­body tar­get­ing both al­pha-synu­cle­in and IGF1R — a de­sign that it be­lieves can lead to bet­ter pen­e­tra­tion of the blood-brain bar­ri­er.

The French phar­ma gi­ant is hand­ing its new biotech part­ner $75 mil­lion in up­front cash, on top of $985 mil­lion in biobucks, $45 mil­lion of which will be near-term mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER